CRM197‐PCV7in low‐risk infants · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
1 finding from 1 review
CRM197‐PCV7in high‐risk infants · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
1 finding from 1 review
OMPC‐PCV7in low‐risk infants · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
1 finding from 1 review
PHiD‐CV10in low‐risk infants · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
1 finding from 1 review
PHiD‐CV11in low‐risk infants · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
1 finding from 1 review
Adverse effects · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
CRM197‐PCV7in low‐risk infants OMPC‐PCV7in low‐risk infants PHiD‐PC10 and PHiD‐PC11 in low‐risk infants CRM197‐PCV7/9 and CRM197‐PCV7 plus TIVin older children · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
1 finding from 1 review
Intervention not reported
VT‐IPD, ITT (random) ( · Children under two years of age
The intervention leads to lower VT‐IPD, ITT (random) ( (high certainty).
1 finding from 1 review
Intervention not reported
All serotypes‐IPD, ITT (random) ( · Children under two years of age
The intervention leads to lower all serotypes‐IPD, ITT (random) ( (high certainty).
1 finding from 1 review
Intervention not reported
X‐ray defined pneumonia, ITT (random) ( · Children under two years of age
The intervention probably leads to lower X‐ray defined pneumonia, ITT (random) ( (moderate certainty).
1 finding from 1 review
Intervention not reported
Clinical pneumonia, ITT (random) ( · Children under two years of age
The intervention probably leads to lower clinical pneumonia, ITT (random) ( (moderate certainty).
1 finding from 1 review